MarketCapExport financials
Sarepta Therapeutics (SRPT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Sarepta Therapeutics SRPT
$ 17.8
1.71%
Facebook
X
Telegram
Sarepta Therapeutics Balance Sheet 2025-1980 | SRPT
Brief overview of Sarepta Therapeutics's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Across five periods, assets reached $3.3 billion versus $3.1 billion initially. Growth of +6.4% reflects gradual development.
The growth rates were balanced: assets changed +6.4%, while liabilities changed -0.5%.
Equity represents 34.1% of assets versus 29.5% initially. The capital structure appears balanced.
Each unit of equity supports about 0.03x of net debt. Dependence on debt remains comfortable.
Cash accounts for 23.9% of assets versus 67.2% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$4.9 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
Sarepta Therapeutics's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1980 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
38.9 M | 47.4 M | 827 M | 593 M | -1.54 B | -1.4 B | 136 M | 853 M | -169 M | -106 M | -56.9 M | -67.2 M | -255 M | -186 M | -38.1 M | -31.7 M | - | - | - |
Long Term Debt |
829 M | 1.14 B | 1.24 B | 1.54 B | 564 M | 80.4 M | 682 M | 421 M | 425 M | 6.04 M | 15 M | 3.74 M | 1.58 M | 1.67 M | 1.76 M | 1.84 M | - | - | - |
Long Term Debt Current |
11.2 M | 13.3 M | 17.8 M | 15.5 M | 15 M | 20.9 M | - | - | - | - | - | 98 K | 92 K | 89 K | 85 K | 81 K | - | - | - |
Total Non Current Liabilities |
1.11 B | 1.7 B | 1.75 B | 2.12 B | 1.77 B | 1.81 B | 740 M | 436 M | 430 M | 12 M | 21.1 M | 10.5 M | 8.41 M | 2.43 M | 2.75 M | 1.09 M | - | - | - |
Total Current Liabilities |
1.1 B | 732 M | 654 M | 620 M | 453 M | 416 M | 265 M | 174 M | 88.3 M | 75.4 M | 62.3 M | 36.9 M | 36 M | 78.9 M | 20.6 M | 45.9 M | - | - | - |
Total Liabilities |
2.21 B | 2.44 B | 2.41 B | 2.74 B | 2.22 B | 2.22 B | 1 B | 610 M | 519 M | 87.4 M | 83.4 M | 47.4 M | 44.4 M | 81.3 M | 23.4 M | - | - | - | - |
Deferred Revenue |
443 M | 130 M | 50.4 M | 89.2 M | 89.2 M | 89.2 M | - | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | - | - | - |
Retained Earnings |
-4.88 B | -4.21 B | -4.45 B | -3.91 B | -3.21 B | -2.85 B | -2.29 B | -1.58 B | -1.22 B | -1.17 B | -899 M | -679 M | -543 M | -431 M | -310 M | - | - | - | - |
Total Assets |
3.35 B | 3.96 B | 3.26 B | 3.13 B | 3.15 B | 2.98 B | 1.82 B | 1.64 B | 1.31 B | 424 M | 274 M | 295 M | 292 M | 205 M | 54.4 M | 46 M | - | - | - |
Cash and Cash Equivalents |
801 M | 1.1 B | 428 M | 967 M | 2.12 B | 1.5 B | 835 M | 371 M | 600 M | 122 M | 80.3 M | 73.6 M | 257 M | 188 M | 39.9 M | 33.6 M | 48.3 M | 11.2 M | - |
Book Value |
1.14 B | 1.53 B | 859 M | 385 M | 928 M | 762 M | 818 M | 1.03 B | 789 M | 337 M | 190 M | 248 M | 247 M | 124 M | 31 M | 46 M | - | - | - |
Total Shareholders Equity |
1.14 B | 1.53 B | 859 M | 385 M | 928 M | 762 M | 818 M | 1.03 B | 789 M | 337 M | 190 M | 248 M | 247 M | 124 M | 31 M | -2.82 M | 23.6 M | 15.7 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Sarepta Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
196 M | 198 M | 199 M | 199 M | 215 M | 214 M | 205 M | 192 M | 170 M | 144 M | 140 M | 141 M | 135 M | 129 M | 53.9 M | 57.6 M | 35.2 M | 39.4 M | 38.6 M | 41.5 M | 63.4 M | 65.3 M | 60.7 M | 80.4 M | 68.2 M | 72.4 M | 65.3 M | 47.7 M | 49.7 M | 50.2 M | 52.2 M | 421 M | 415 M | 439 M | 431 M | 431 M | 37.7 M | 431 M | 431 M | 17.7 M | - | - | - | 26.8 M | - | - | 1.45 M | 7.1 M | 1.5 M | 1.52 M | 1.55 M | 1.67 M | 1.58 M | 1.58 M | 1.58 M | 1.76 M | 1.67 M | 1.67 M | 1.67 M | 1.76 M | 1.76 M | 1.76 M | 1.76 M |
Total Non Current Liabilities |
981 M | 1.16 B | 1.17 B | 1.11 B | 1.25 B | 1.4 B | 1.72 B | 1.7 B | 1.68 B | 1.66 B | 1.65 B | 1.75 B | 1.89 B | 1.89 B | 1.81 B | 2.12 B | 2.12 B | 1.72 B | 1.74 B | 1.77 B | 1.82 B | 1.85 B | 1.87 B | 1.81 B | 1.51 B | 1.49 B | 1.5 B | 740 M | 491 M | 486 M | 478 M | 436 M | 429 M | 443 M | 432 M | 430 M | 32.7 M | 6.41 M | 7.76 M | 12 M | 13.8 M | 15.7 M | 19.2 M | 21.1 M | 23.8 M | 27.4 M | 8.04 M | 10.5 M | 10.1 M | 7.98 M | 8.67 M | 8.41 M | 4.8 M | 757 K | 755 K | 760 K | 758 K | 760 K | 760 K | 993 K | 993 K | 993 K | 993 K |
Total Liabilities |
1.64 B | 1.66 B | 1.67 B | 2.21 B | 2.17 B | 2.32 B | 2.32 B | 2.44 B | 2.38 B | 2.35 B | 2.26 B | 2.41 B | 2.35 B | 2.38 B | 2.35 B | 2.74 B | 2.73 B | 2.27 B | 2.2 B | 2.22 B | 2.19 B | 2.27 B | 2.23 B | 2.22 B | 1.89 B | 1.84 B | 1.8 B | 1 B | 707 M | 649 M | 615 M | 610 M | 543 M | 548 M | 524 M | 519 M | 103 M | 72.4 M | 82.4 M | 87.4 M | 78.7 M | 82.6 M | 74.4 M | 83.4 M | 61.5 M | 66.3 M | 41.9 M | 47.4 M | 32.9 M | 37.4 M | 46.4 M | 44.4 M | 44.4 M | 44.4 M | 44.4 M | 81.3 M | 81.3 M | 81.3 M | 81.3 M | - | - | - | - |
Deferred Revenue |
105 M | 110 M | 116 M | 443 M | 485 M | 395 M | 44.9 M | 130 M | 127 M | 122 M | 112 M | 50.4 M | 22.5 M | 45 M | 67.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.3 M | 91.1 M | 3.3 M | 3.3 M | 3.3 M | 3.98 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.36 M | 3.32 M | 3.36 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M |
Retained Earnings |
-4.58 B | -4.55 B | -4.55 B | -4.88 B | -4.64 B | -4.46 B | -4.66 B | -4.21 B | -4.37 B | -4.4 B | -4.41 B | -4.45 B | -4.49 B | -4.45 B | -4.43 B | -3.91 B | -3.8 B | -3.54 B | -3.31 B | -3.21 B | -3.08 B | -3.04 B | -2.96 B | -2.85 B | -2.66 B | -2.46 B | -2.31 B | -2.29 B | -2.06 B | -1.93 B | -1.66 B | -1.58 B | -1.44 B | -1.36 B | -1.25 B | -1.22 B | -1.19 B | -1.15 B | -1.08 B | -1.17 B | -1.08 B | -1.02 B | -959 M | -899 M | -834 M | -782 M | -741 M | -679 M | -635 M | -605 M | -679 M | -543 M | -543 M | -543 M | - | - | - | - | - | - | - | - | - |
Total Assets |
3.17 B | 3.19 B | 3.18 B | 3.35 B | 3.49 B | 3.68 B | 3.47 B | 3.96 B | 3.6 B | 3.42 B | 3.22 B | 3.26 B | 3.11 B | 3.13 B | 3.06 B | 3.13 B | 3.16 B | 3 B | 3.06 B | 3.15 B | 2.66 B | 2.76 B | 2.77 B | 2.98 B | 2.78 B | 2.88 B | 2.95 B | 1.82 B | 1.7 B | 1.75 B | 1.96 B | 1.64 B | 1.18 B | 1.25 B | 1.3 B | 1.31 B | 800 M | 450 M | 512 M | 424 M | 487 M | 204 M | 213 M | 274 M | 185 M | 232 M | 243 M | 295 M | 319 M | 337 M | 275 M | 292 M | 292 M | 292 M | 292 M | 205 M | 205 M | 205 M | 205 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Cash and Cash Equivalents |
483 M | 581 M | 478 M | 814 M | 626 M | 526 M | 256 M | 1.12 B | 213 M | 399 M | 443 M | 444 M | 561 M | 871 M | 891 M | 986 M | 1.06 B | 887 M | 1.24 B | 2.13 B | 1.61 B | 1.71 B | 1.49 B | 1.51 B | 1.48 B | 1.65 B | 1.77 B | 844 M | 733 M | 817 M | 737 M | 371 M | 210 M | 410 M | 557 M | 600 M | 618 M | 168 M | 275 M | 123 M | 395 M | 112 M | 38 M | 80.3 M | 55.8 M | 69.5 M | 74.4 M | 73.6 M | 52.3 M | 103 M | 49.1 M | 257 M | 257 M | 257 M | 257 M | 188 M | 188 M | 188 M | 188 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M |
Book Value |
1.53 B | 1.53 B | 1.51 B | 1.14 B | 1.32 B | 1.36 B | 1.14 B | 1.53 B | 1.22 B | 1.08 B | 961 M | 859 M | 764 M | 741 M | 713 M | 385 M | 431 M | 726 M | 857 M | 928 M | 470 M | 485 M | 535 M | 762 M | 892 M | 1.04 B | 1.14 B | 818 M | 995 M | 1.1 B | 1.35 B | 1.03 B | 640 M | 699 M | 777 M | 789 M | 697 M | 378 M | 429 M | 337 M | 409 M | 121 M | 139 M | 190 M | 123 M | 165 M | 201 M | 248 M | 286 M | 300 M | 229 M | 247 M | 247 M | 247 M | 247 M | 124 M | 124 M | 124 M | 124 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Total Shareholders Equity |
1.53 B | 1.53 B | 1.51 B | 1.14 B | 1.5 B | 1.4 B | 1.19 B | 1.53 B | 1.22 B | 1.08 B | 961 M | 859 M | 764 M | 741 M | 713 M | 385 M | 431 M | 726 M | 857 M | 928 M | 470 M | 485 M | 535 M | 762 M | 892 M | 1.04 B | 1.14 B | 818 M | 995 M | 1.1 B | 1.35 B | 1.03 B | 640 M | 699 M | 777 M | 789 M | 697 M | 378 M | 429 M | 337 M | 409 M | 121 M | 139 M | 190 M | 123 M | 165 M | 201 M | 248 M | 286 M | 300 M | 229 M | 247 M | 247 M | 247 M | 247 M | 124 M | 124 M | 124 M | 124 M | 31 M | 31 M | 31 M | 31 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sarepta Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Annexon
ANNX
|
$ 4.21 | 4.99 % | $ 653 M |  USA |
 |
AbbVie
ABBV
|
$ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
$ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
$ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
$ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
$ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
- | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
$ 7.93 | 0.51 % | $ 427 M | USA |